PMDA drug package insert
リスティーゴ皮下注280mg
PMDA Prescription drug · ユーシービージャパン株式会社 · package insert Jul 28, 2026
Key facts
| Brand names | リスティーゴ皮下注280mg, リスティーゴ皮下注420mg |
|---|---|
| Nonproprietary names | ロザノリキシズマブ（遺伝子組換え） |
| Companies | 製造販売元／ユーシービージャパン株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗FcRnモノクローナル抗体製剤 |
| Therapeutic category codes | 876399 |
| YJ codes | 6399432A1028, 6399432A2024 |
| Approval numbers | 30500AMX00274000, 30700AMX00091000 |
| Package insert edition | 第8版 |
| Package insert date | Jul 28, 2026 |
| PMDA document key | 820110_6399432A1028_1 |
| PMDA company code | 820110 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: